About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Active Not RecruitingPhase 1NCT03190278

Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase I, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of Universal Chimeric Antigen Receptor T-cell (UCART) targeting the Cluster of Differentiation 123 (CD1...

Lead sponsor: Cellectis S.A.•8 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Cellectis S.A.

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with relapsed or primary refractory AML (as defined in World Health Organization \[WHO\] criteria) with ≥5% bone marrow blasts
•Patients with CD123+ blast cells (verified by flow cytometry)
•Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of ≤1
•Adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac function based on the last assessment performed within screening period
•(Dose-escalation) Identified donor and transplant strategy prior to lymphodepletion (LD)
•Other criteria may apply

Exclusion Criteria

•Patients with acute promyelocytic leukemia (APL) or central nervous system (CNS) Leukemia
•Previous investigation gene or cell therapy (including CAR)
•\> 1 prior allogeneic stem cell transplantations (SCTs)
•Prior treatment with rituximab or other anti-cluster of differentiation 20 (anti-CD20) therapy within 3 months
•Any known active or uncontrolled infection
•Other criteria may apply

Related studies

RECRUITINGPhase 1/2

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

NCT07523555 · Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, and more

RECRUITINGPhase 1

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT05143996 · Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)

RECRUITINGPhase 1

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

NCT06714591 · Relapsed/Refractory Acute Myeloid Leukemia

RECRUITINGPhase 1

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT05924750 · Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

RECRUITINGPhase 2

Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia

NCT06869265 · Acute Myeloid Leukemia (AML), High Risk Acute Myeloid Leukemia(AML), and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 7, 2025Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

PhasePHASE1

Enrollment29

Start dateJun 2017

Last updatedAug 7, 2025

Condition

Relapsed/Refractory Acute Myeloid Leukemia

Locations shown

University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center

San Francisco, California

H. Lee Moffitt Cancer Center & Research Institute

Tampa, Florida

Northwestern University

Chicago, Illinois

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 7, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions